Inovio expects an FDA decision on INO-3107 by Oct. 30, 2026, with commercial preparations underway.
The company estimates cash, equivalents and investments will fund operations into late Q1 2027, including proceeds from a July offering.
Inovio said it continues discussions with potential partners to accelerate next-generation DNA medicine programs.
The current average analyst rating on the shares is "buy", with 2 "strong buy" or "buy", 2 "hold", and no "sell" or "strong sell" ratings.
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $2.50, about 226.5% above its August 11 closing price of $0.77.
Q2 loss narrows on warrant gain and lower expenses
Inovio said its Q2 net loss narrowed year over year, driven by a non-cash warrant gain.
The company said Q2 operating expenses fell because of lower employee and consultant compensation, reduced engineering services, and lower inventory expenses.
INO•
